Climate change is significantly altering the air we breathe by increasing both harmful pollutants and allergens that affect human health. Rising temperatures and elevated CO2 levels are creating longer, more intense pollen seasons while also increasing ground-level ozone, particulate matter, and other respiratory irritants. These changes disproportionately impact vulnerable populations worldwide, leading to increased respiratory infections, asthma exacerbations, and allergic diseases, making climate change not just an environmental issue but a direct threat to public health .

The authors highlight that while urban gardens and green roofs provide crucial benefits like air filtration and cooling, many commonly planted species like birch trees and grasses produce high amounts of allergenic pollen that affects up to 40% of Europeans

Recent advances in nanotechnology have generated concerns regarding nanoparticles' prevalence, dispersion, destiny, and environmental migration.

This review highlights how nurse practitioners can strengthen Alzheimer’s disease care by supporting earlier diagnosis and access to treatment, which is essential for maintaining quality of life. Expanding their role helps reduce barriers in the healthcare system, ensuring people with Alzheimer’s receive timely care that promotes better health and well-being.

The article presents PI4AD, a computational medicine framework that integrates multi-omics data, systems biology, and artificial neural networks to prioritize therapeutic targets for Alzheimer's disease (AD). PI4AD recovers clinically validated targets like APP and ESR1, confirming its prioritization efficacy. The framework identifies Ras signaling as a central therapeutic hub, complementing traditional amyloid/tau-focused approaches. Crosstalk analysis reveals critical nodal genes (e.g., HRAS and MAPK1) and drug repurposing opportunities, bridging genetic insights with pathway-level biology.

The article suggest that beta-amyloid protein (Aβ) has a significant indirect effect on neurogranin (Ng) through key synaptic mediators such as SYT1 and GAP43 during the preclinical stages of Alzheimer’s disease (AD). These findings highlight the crucial role of SYT1 and GAP43 in mediating beta-amyloid-induced synaptic dysfunction, offering potential early biomarkers and therapeutic targets for AD progression.

The article discusses the potential of artificial intelligence (AI) in revolutionizing drug discovery for Alzheimer's disease (AD) and delirium. It explores how AI can facilitate target identification, small molecule and protein-based drug design, and optimization of pharmacokinetic properties to address the challenges in developing effective treatments for these two brain diseases.